BiotechReadouts
Get updates

Bristol-Myers Squibb (BMY): next trial readout expected around 2026-08-31

Trials that could report in the next 12 months: 18
BiopharmaCTG

Catalyst timeline

Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything BMY is running — see methodology.

  1. 2026-08-31in 2wA Phase 1 Study of Navlimetostat Tablet Formulations
  2. 2026-09-05in 2wA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
  3. 2026-09-30in 6wA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
  4. 2026-10-06in 7wA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
  5. 2026-10-12in 8wA Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
  6. 2026-10-19in 9wA Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
  7. 2026-10-19in 9wA Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
  8. 2026-10-31in 10wA Rollover Study of CC-122
  9. 2026-11-01in 11wA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
  10. 2026-11-02in 11wA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
  11. 2026-11-17in 13wA Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
  12. 2026-11-18in 13wA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
  13. 2029-08-25in 157wPan Tumor Rollover Study
  14. 2029-10-15in 165wA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  15. 2029-11-28in 171wA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
  16. 2030-02-02in 180wA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
  17. 2030-09-18in 213wA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
  18. 2030-11-08in 220wA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Pipeline

ProgramPhaseStatusPrimary completionTrial
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combinatio…Phase 2Recruitingstill enrolling patients2030-11-08NCT07221149
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent C…Phase 3Recruitingstill enrolling patients2030-09-18NCT07361497
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combinatio…Phase 2Recruitingstill enrolling patients2030-02-02NCT07221357
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitami…Phase 1Recruitingstill enrolling patients2029-11-28NCT07293351
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or …Phase 1Recruitingstill enrolling patients2029-10-15NCT07291076
Pan Tumor Rollover StudyPhase 2Recruitingstill enrolling patients2029-08-25NCT03899155
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adul…Phase 3Active Not Recruitingenrolled, still running2026-11-18NCT05946941
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-9…Phase 1Recruitingstill enrolling patients2026-11-17NCT07283263
+ 10 more tracked trials
ProgramPhaseStatusPrimary completionTrial
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment…Phase 3Recruitingstill enrolling patients2026-11-02NCT06951711
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment…Phase 3Recruitingstill enrolling patients2026-11-01NCT06951698
A Rollover Study of CC-122Phase 1Active Not Recruitingenrolled, still running2026-10-31NCT05688475
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-9…Phase 3Active Not Recruitingenrolled, still running2026-10-19NCT05620407
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared…Phase 3Active Not Recruitingenrolled, still running2026-10-19NCT05617677
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 …Phase 1Recruitingstill enrolling patients2026-10-12NCT05372354
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-9862…Phase 3Active Not Recruitingenrolled, still running2026-10-06NCT06003426
A Study of BMS-986449 With and Without Nivolumab in Participants With …Phase 1Active Not Recruitingenrolled, still running2026-09-30NCT05888831
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tu…Phase 1Recruitingstill enrolling patients2026-09-05NCT06730750
A Phase 1 Study of Navlimetostat Tablet FormulationsPhase 1Recruitingstill enrolling patients2026-08-31NCT07544628

Status-change history

Every ClinicalTrials.gov change recorded for BMY's trials — a running history no other tracker shows.

No status changes detected yet for this ticker.

Frequently asked

When is BMY's next PDUFA date?

No disclosed PDUFA date is currently tracked for this ticker.

What phase is BMY's lead program in?

Phase 3 — active not recruiting.

Where does this data come from?

ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.